BioCryst Upgraded To Outperform

September 29, 2010 9:35am Comments

Rodman & Renshaw has upgraded BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) from Market Perform to Market Outperform with a $7 price target.

BioCryst Pharmaceuticals closed yesterday at $4.82.

Is AAPL a Buy, Sell or Hold? Click Here.

Posted-In: biocryst Rodman & Renshaw Upgrades Analyst Ratings

Need analyst data?
Click here to see licensing options.

Stock	Firm	Action	PT
SEDG	B of A Securities	Maintains	411.0
PTLO	Piper Sandler	Maintains	28.0
AOUT	Lake Street	Maintains	26.0
RAPT	Piper Sandler	Maintains	52.0
OCX	Lake Street	Maintains	6.0

1	NTR: What to Expect from Nutrien's Earnings
2	BRK, DIA: Wall Street Rebounds Ahead Of Palantir Earnings: What's Moving M...
3	VWAGY, RIVN: Rivian Q2 Earnings: Revenue Beat, EPS Miss, Delivery Guida...
4	AMD, MSFT: AMD Aims To Dethrone Nvidia In AI Race—Here...
5	AMD, $SOL: Bitcoin, Ethereum, Dogecoin, XRP Mirror...
6	DHR: Danaher Stock Closes Near Day's...
7	ANET, AMGN: Stock Market Today: US Stoc...

1	META, QQQ: S&P 500 Primed For Correction, But It Comes With Major Buying Oppor...
2	PLTR, CAT: Mohamed El-Erian Says Contrast Between Palantir, Caterpillar E...
3	MSTR, GDX: Peter Schiff Says Gold Outperformed Bitcoin, Michael...
4	UBER, TSLA: Tesla Isn't The Only Company To '...
5	UBER, AMD: McDonald's, Uber Technologies...
6	USO, IEO: Nikki Haley Rips Trump Tar...
7	FLYW: Flywire Stock Jumps 24...

Market Overview